Agenus (AGEN) : Traders are bullish on Agenus (AGEN) as it has outperformed the S&P 500 by a wide margin of 27.54% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 16.19%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 16.11% in the last 1 week, and is up 31.83% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 18.53% and the 50-Day Moving Average is 29.62%. Agenus Inc. is up 57.67% in the last 3-month period. Year-to-Date the stock performance stands at 22.25%.
Agenus (NASDAQ:AGEN): stock turned positive on Friday. Though the stock opened at $5.42, the bulls momentum made the stock top out at $5.7 level for the day. The stock recorded a low of $5.36 and closed the trading day at $5.55, in the green by 3.16%. The total traded volume for the day was 2,312,904. The stock had closed at $5.38 in the previous days trading.
Also, Equity Analysts at the Jefferies maintains the rating on Agenus (NASDAQ:AGEN). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $6 per share to $7 per share. The rating by the firm was issued on July 29, 2016.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).